LUND, Sweden--(BUSINESS WIRE)--Regulatory News:
Camurus AB (Nasdaq Stockholm: CAMX) today announces that the Annual Report for 2015 now is available at the company’s website: www.camurus.com
About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise.
